Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 9/20 | 0.60 |
| ▸ | NOS1 | P29475 | 3/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | CASP7 | P55210 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PAH | P00439 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | BLM | P54132 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10507812 | 0.99 | HPRT1 (0.59) | HPRT1NOS1USP2CASP7HSD17B10 | |
| Phosphoric Acid SCHEMBL571369 | 0.95 | HPRT1 (0.64) | HPRT1NOS1 | |
| SCHEMBL7745028 | 0.91 | HPRT1 (0.64) | HPRT1NOS1USP2CASP7HSD17B10 | |
| SCHEMBL10508833 | 0.89 | HPRT1 (0.55) | HPRT1NOS1USP2CASP7HSD17B10 | |
| SCHEMBL10919055 | 0.86 | HPRT1 (0.58) | HPRT1NOS1USP2CASP7HSD17B10 | |
| SCHEMBL10509781 | 0.86 | HPRT1 (0.55) | HPRT1NOS1USP2CASP7HSD17B10 | |
| SCHEMBL10919050 | 0.85 | HPRT1 (0.57) | HPRT1NOS1USP2CASP7HSD17B10 | |
| SCHEMBL146837 | 0.85 | HPRT1 (0.58) | HPRT1NOS1USP2CASP7HSD17B10 | |
| SCHEMBL9172629 | 0.85 | HPRT1 (0.69) | HPRT1 | |
| SCHEMBL7192798 | 0.84 | HPRT1 (0.57) | HPRT1NOS1USP2CASP7HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 307 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160346287-A1 | METHOD OF TREATING VIRAL INFECTIONS | EPIPHANY BIOSCIENCES, INC. | 2016-12-01 | — | — | US | claimed |
| US-20150050241-A1 | METHOD OF TREATING VIRAL INFECTIONS | EPIPHANY BIOSCIENCES, INC. | 2015-02-19 | — | — | US | claimed |
| WO-2014047562-A2 | METHOD OF TREATING AND/OR PREVENTING SHINGLES AND METHOD OF TREATING AND/OR PREVENTING ZOSTER ASSOCIATED PAIN | EPIPHANY BIOSCIENCES (US) | 2014-03-27 | — | — | WO | claimed |
| EP-1720856-B1 | HIV INTEGRASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-08-14 | — | — | EP | claimed |
| US-8455497-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-04 | — | — | US | claimed |
| EP-1686113-B1 | Inhibitors of aspartyl protease | VERTEX PHARMA (US) | 2011-11-23 | — | — | EP | claimed |
| JP-4503896-B2 | — | — | 2010-07-14 | — | — | JP | claimed |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-05 | — | — | US | claimed |
| WO-2009120358-A1 | OLIGOMER-NITROGENOUS BASE CONJUGATES | NEKTAR THERAPEUTICS (US) | 2009-10-01 | — | — | WO | claimed |
| US-20090053172-A1 | HETEROCYCLIC COMPOUNDS AS CCR5 ANTAGONISTS | AQUINO CHRISTOPHER JOSEPH | 2009-02-26 | — | — | US | claimed |
| EP-1194404-A1 | INHIBITORS OF ASPARTYL PROTEASE | Vertex Pharmaceuticals Incorporated (US) | 2002-04-10 | — | — | EP | claimed |
| EP-1131104-A1 | ANTIVIRAL FORMULATIONS COMPRISING PROPYLENE GLYCOL AND AN ISOPROPYL ALKANOIC ACID ESTER | MEDIVIR AB (SE) | 2001-09-12 | — | — | EP | claimed |
| WO-2000076961-A1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2000-12-21 | — | — | WO | claimed |
| WO-2000029027-A1 | ANTIVIRAL FORMULATIONS COMPRISING PROPYLENE GLYCOL AND AN ISOPROPYL ALKANOIC ACID ESTER | MEDIVIR AB (SE) | 2000-05-25 | — | — | WO | claimed |
| WO-1996022098-A1 | USE OF ACYCLIC PURINE DERIVATIVES FOR TREATING RESTENOSIS | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-07-25 | — | — | WO | claimed |
| EP-0165289-B1 | NOVEL DERIVATIVES OF GUANINE | Medivir Aktiebolag (SE) | 1989-04-05 | — | — | EP | claimed |
| US-4798833-A | VIRICIDES | ASTRA LAKEMEDEL AKTIEBOLAG (SE) | 1989-01-17 | — | — | US | claimed |
| EP-0165289-A1 | NOVEL DERIVATIVES OF GUANINE. | ASTRA LAEKEMEDEL AB (SE) | 1985-12-27 | — | — | EP | claimed |
| WO-1985002845-A1 | NOVEL DERIVATIVES OF GUANINE | Astra Läkemedel Aktiebolag (SE) | 1985-07-04 | — | — | WO | claimed |
| EP-0146516-A2 | Derivatives of Guanine, process for their preparation and a pharmaceutical preparation | Astra Läkemedel Aktiebolag (SE) | 1985-06-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160346287-A1 | METHOD OF TREATING VIRAL INFECTIONS | IFNG, BCL9, GDA | HPRT1 13/4885NOS1 3011/4885USP2 2970/4885 |
| US-20090053172-A1 | HETEROCYCLIC COMPOUNDS AS CCR5 ANTAGONISTS | CCR5, CXCR3, CCR1 | HPRT1 79/4885NOS1 1001/4885USP2 4833/4885 |
| US-20150050241-A1 | METHOD OF TREATING VIRAL INFECTIONS | IFNG, BCL9, GDA | HPRT1 13/4885NOS1 3011/4885USP2 2970/4885 |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | SPINT2, DNPEP, PRSS1 | HPRT1 1520/4885NOS1 3069/4885USP2 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.